Stay updated on IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRecord history now includes a new entry: Revision: v3.4.2; the previous funding notice and Revision: v3.4.1 have been removed.SummaryDifference0.5%

- Check21 days agoChange DetectedA new site-wide funding-status notice was added and the page revision updated from v3.4.0 to v3.4.1.SummaryDifference0.6%

- Check28 days agoChange DetectedThe history page now includes a glossary toggle and explanatory color-coding for changes. It also shows an updated revision label (v3.4.0) replacing the previous version (v3.3.4) and includes capitalization adjustments.SummaryDifference0.7%

- Check42 days agoChange DetectedThe history now shows a new revision entry v3.3.4 and the previous entry v3.3.3 has been removed.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision: v3.3.3 was added; HHS Vulnerability Disclosure and Revision: v3.3.2 were removed.SummaryDifference0.1%

- Check92 days agoChange DetectedRevision history now lists version v3.3.2. The previous version v3.2.0 has been removed from the history.SummaryDifference0.1%

Stay in the know with updates to IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial page.